Core Viewpoint - IM Cannabis Corp. has signed a non-binding indicative term sheet to acquire a 60% equity interest in a quantum computing bio data company for up to $54 million, aiming to enhance long-term growth opportunities and shareholder value [1][4]. Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on premium cannabis products for medical patients in these significant markets [6][7]. - The company aims for sustainable and profitable growth by leveraging a data-driven approach and a globally sourced product supply chain [6]. Proposed Transaction Details - The acquisition involves an aggregate consideration of up to $54 million, which will be paid in cash, IMC shares, and potential earn-out payments based on performance milestones [2]. - The transaction is subject to due diligence, negotiation of definitive agreements, and necessary corporate and regulatory approvals [3]. Strategic Intent - This move follows the company's decision to explore additional business activities to enhance growth opportunities and create further shareholder value [4].